The investigational sublingual allergy immunotherapy tablet (GRAZAX®) meets
primary endpoint in a study of paediatric patients with a history of grass
pollen allergies.
The investigational sublingual Grass (Phleum Pratense) Allergy Immunotherapy
Tablet (AIT) has met the primary endpoint in a Phase III study of paediatric
patients in the U.S. with a history of grass pollen induced rhinoconjunctivitis
with or without asthma.
The study was conducted by Merck, ALK's strategic partner in North America, and
was a U.S. multicenter, randomized, placebo-controlled, double-blind,
parallel-group clinical trial. The trial was evaluating the efficacy of the
grass sublingual tablet versus placebo in the treatment of grass pollen-induced
rhinoconjunctivitis based on the combined rhinoconjunctivitis daily symptom
score and rhinoconjunctivitis daily medication score averaged over the entire
grass pollen season. In the study 345 children were randomized to receive
either placebo or grass tablet. The study met its primary endpoint.
The data will be presented by Merck at the annual meeting of the American
Academy of Allergy Asthma and Immunology (AAAAI), February 26 to March 2, 2010,
in New Orleans, USA.
ALK-Abelló A/S
Jens Bager, President & CEO
For further information please contact:
Jens Bager, President and CEO, tel. +45 4574 7576
Investor Relations: Per Plotnikof, tel +45 4574 7527, mobile +45 2261 2525
Press: Martin Barlebo, tel. + 45 4574 7901, mobile + 45 2064 1143
